






Arno Therapeutics, Inc. - Product Pipeline Review - 2014























































  info@wiseguyreports.com  |   
 Chat with us   |    +1 (339) 368 6938 (US)  |     +44 208 133 9349 (UK) 



 Login    Register 






















Home


Report Categories







Premium Reports

Access to 600000+ Premium Reports











  
                                Aerospace & Defense
                              









  
                                Agri & Food
                              









  
                                Automotive
                              









  
                                Basic Materials
                              











  
                                Consumer Goods & Retail
                              









  
                                Energy
                              









  
                                Life Sciences
                              









  
                                Manufacturing & Construction
                              











  
                                Services
                              









  
                                Telecom & IT
                              









  
                                Education
                              









  
                                Security & Intelligence Systems
                              











  
                                Technology
                              









  
                                Company Reports
                              










Report Categories 










Aerospace & Defense
                





Agri & Food
                





Automotive
                





Basic Materials
                







Consumer Goods & Retail
                





Energy
                





Life Sciences
                





Manufacturing & Construction
                







Services
                





Telecom & IT
                





Education
                





Security & Intelligence Systems
                







Technology
                





Company Reports
                








Publisher
Knowledgestore

Countries 
              


Browse by Country
Browse by Continent
Browse by Group / Region



 Conferences
              


Upcoming Conferences
Seminars




 Conferences
              


Upcoming Conferences
Seminars




Countries 

Browse by Country
Browse by Continent
Browse by Group / Region



News & Blog

 Press Release
Blog



News & Blogs

 Press Release
Blogs


FAQs

About Us

About Our Company
Our Team
Life At WGR


Careers
Contact Us











                                         There are no items currently in your basket.
                                     













There are no items currently in your basket!














  




































Search 
                






 














Home
All Reports
Arno Therapeutics, Inc. - Product Pipeline Review - 2014









 


  Arno Therapeutics, Inc. - Product Pipeline Review - 2014


WGR11060
10 
                  July, 2014 
Global
35 pages 
Global Markets Direct






















Description




Table of Content




Sample Report




Enquiry before buy




Related Reports





Arno Therapeutics, Inc. - Product Pipeline Review - 2014SummaryGlobal Markets Direct’s, ‘Arno Therapeutics, Inc. - Product Pipeline Review - 2014’, provides an overview of the Arno Therapeutics, Inc.’s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Arno Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.Scope- The report provides brief overview of Arno Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries- The report reviews current pipeline of Arno Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones - Special feature on out-licensed and partnered product portfolio- The report summarizes all the dormant and discontinued pipeline projects- Latest company statement - Latest news and deals relating to the Arno Therapeutics, Inc.’s pipeline productsReasons to buy- Evaluate Arno Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline- Assess the growth potential of Arno Therapeutics, Inc. in its therapy areas of focus- Identify new drug targets and therapeutic classes in the Arno Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps- Develop strategic initiatives by understanding the focus areas of Arno Therapeutics, Inc. and exploit collaboration and partnership opportunities- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arno Therapeutics, Inc.- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Explore the dormant and discontinued projects of Arno Therapeutics, Inc. and identify potential opportunities in those areas- Avoid Intellectual Property Rights related issues


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Arno Therapeutics, Inc. Snapshot 4Arno Therapeutics, Inc. Overview 4Key Information 4Key Facts 4Arno Therapeutics, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Arno Therapeutics, Inc. - Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products - Monotherapy 9Arno Therapeutics, Inc. - Pipeline Products Glance 10Arno Therapeutics, Inc. - Clinical Stage Pipeline Products 10Phase I Products/Combination Treatment Modalities 10Arno Therapeutics, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Arno Therapeutics, Inc. - Drug Profiles 12AR-42 12Product Description 12Mechanism of Action 12R&D Progress 12onapristone ER 14Product Description 14Mechanism of Action 14R&D Progress 14AR-12 16Product Description 16Mechanism of Action 16R&D Progress 16Arno Therapeutics, Inc. - Pipeline Analysis 18Arno Therapeutics, Inc. - Pipeline Products by Target 18Arno Therapeutics, Inc. - Pipeline Products by Route of Administration 19Arno Therapeutics, Inc. - Pipeline Products by Molecule Type 20Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action 21Arno Therapeutics, Inc. - Recent Pipeline Updates 22Arno Therapeutics, Inc. - Dormant Projects 27Arno Therapeutics, Inc. - Discontinued Pipeline Products 28Discontinued Pipeline Product Profiles 28AR-67 28Arno Therapeutics, Inc. - Company Statement 29Arno Therapeutics, Inc. - Locations And Subsidiaries 33Head Office 33Appendix 34Methodology 34Coverage 34Secondary Research 34Primary Research 34Expert Panel Validation 34Contact Us 35Disclaimer 35List of TablesArno Therapeutics, Inc., Key Information 4Arno Therapeutics, Inc., Key Facts 4Arno Therapeutics, Inc. - Pipeline by Indication, 2014 7Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9Arno Therapeutics, Inc. - Phase I, 2014 10Arno Therapeutics, Inc. - Preclinical, 2014 11Arno Therapeutics, Inc. - Pipeline by Target, 2014 18Arno Therapeutics, Inc. - Pipeline by Route of Administration, 2014 19Arno Therapeutics, Inc. - Pipeline by Molecule Type, 2014 20Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 21Arno Therapeutics, Inc. - Recent Pipeline Updates, 2014 22Arno Therapeutics, Inc. - Dormant Developmental Projects,2014 27Arno Therapeutics, Inc. - Discontinued Pipeline Products, 2014 28List of FiguresArno Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9Arno Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 18Arno Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 19Arno Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 20Arno Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21







                                Request a Sample Report
                                




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Do you have any Specific field of Interest?*

















Confirm


 








Make an enquiry before buying this Report




Name:*










Email:*


(Optional: Request you to please fill in your Corporate Email-ID)



Job Title:*





Company:*





Phone No:*





Your Country:*

--select country--
Afghanistan
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antigua & Barbuda
Argentina
Armenia
Aruba
Australia
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodja
Cameroon
Canada
Cape Verde
Cayman Islands
Central African Republic
Chad
Chile
China
Colombia
Comoros
Congo-Brazzaville
Congo-Kinshasa
Cook Islands
Costa Rica
Cote d"Ivoire
Croatia
Cuba
Cyprus
Czech Republic
Denmark
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland (Malvinas)
Faroes
Fiji
Finland
France
French-Guiana
Tahiti(French Polinesia)
Gabon
Gambia
Georgia
Germany
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guinea
Guinea-Bissau
Guyana
Haiti
Vatican City
Honduras
Hong Kong
Hungary
Iceland
India
Indonesia
Iran
Iraq
Ireland
Israel
Italy
Jamaica
Japan
Jordan
Kazakhstan
Kenya
Kiribati
North Korea
South Korea
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macao
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montserrat
Morocco
Mozambique
Myanmar
Namibia
Nauru
Nepal
Netherlands
Netherlands Antilles
New Caledonia
New Zealand
Nicaragua
Niger
Nigeria
Norfolk
Northern Mariana
Norway
Oman
Pakistan
Palau
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn
Poland
Portugal
Puerto Rico
Qatar
Reunion
Romania
Russian Federation
Rwanda
Saint Helena
Saint Lucia
Saint Pierre and Miquelon
St Vincent & the Grenadines
Samoa
San Marino
Sao Tome & Principe
Saudi Arabia
Senegal
Seychelles
Sierra Leone
Singapore
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
Spain
Sri Lanka
Sudan
Suriname
Svalbard and Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Taiwan
Tajikistan
Tanzania
Thailand
Togo
Tokelau
Tonga
Trinidad & Tobago
Tunisia
Turkey
Turkmenistan
Turks and Caicos Islands
Tuvalu
Uganda
Ukraine
United Arab Emirates
United Kingdom
United States of America
Uruguay
Uzbekistan
Vanuatu
Venezuela
Viet Nam
Virgin Islands British
Virgin Islands US
Wales
Western Sahara
Yemen
Zambia
Zimbabwe
Timor-Leste
Curacao
St Kitts & Nevis
Sint Maarten
Guernsey
Isle of Man
Jersey
Niue
Montenegro



Your Enquiry*

















Confirm


 
















Purchase this Market Research Report







 USD




 GBP




 EURO




 YEN




 INR







                        1-user PDF
                         
                          $1,500.00
                        

 
                        Site PDF 
                         
                          $3,000.00
                        

 
                        Enterprise PDF 
                         
                          $4,500.00
                        





  1-user PDF
  
 
    1,153.95
   

 
  Site PDF 
  
 
  2,307.90
  

 
  Enterprise PDF 
  
 
  3,461.85
  





  1-user PDF
  
 
    1,286.40
   

 
  Site PDF 
  
 
  2,572.80
  

 
  Enterprise PDF 
  
 
  3,859.20
  





  1-user PDF
  
 
    166,647.00
   

 
  Site PDF 
  
 
  333,294.00
  

 
  Enterprise PDF 
  
 
  499,941.00
  





  1-user PDF
  
 
    96,667.50
   

 
  Site PDF 
  
 
  193,335.00
  

 
  Enterprise PDF 
  
 
  290,002.50
  









Add To Cart
BUY NOW





 















  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form









  Email Report


  Sample Report




  Save Page


  Any Questions




  Download information


  Check Discount




  Download Order Form






Contact Us










Akash Anand
Domain Head Business Development
sales@wiseguyreports.com
+1 (646) 843 9312 (US)
+44 208 133 9349 (UK)













Rishabh Arora
Domain Head Business Development
sales@wiseguyreports.com
+44-208-133-9346













Abu Koshy
Domain Head Business Development
sales@wiseguyreports.com
+1 339 368 6938










Related Reports








                  ×
              
Tell a friend about this report 




Your Name:*





Your Email:*





Friend's Name:*





Friend's Email:*





Your Enquiry*









Send


 





































Arno Therapeutics, Inc.: Private Company Information - Bloomberg









































  





















































































July 24, 2017 2:45 AM ET
Biotechnology

Company Overview of Arno Therapeutics, Inc.



Snapshot People




Company Overview
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company’s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various ant...
Arno Therapeutics, Inc., a biopharmaceutical company, develops products for the treatment of cancer and other life threatening diseases. The company’s product development pipeline includes Onapristone, a type 1 anti-progestin hormone blocker that is in Phase I/II clinical study for the treatment of breast, endometrial, and others solid tumors in post-menopausal women; and advanced castration-resistant prostate cancer in men. Its product development pipeline also consists of AR-12, an orally available cancer treatment, which has completed Phase I clinical study for the treatment of solid tumors and hematological malignancies, as well as in Pre-clinical studies for the treatment of various anti-microbial targets. In addition, the company’s product development pipeline comprises AR-42, a novel orally available cancer therapy that is in Phase I investigator-initiated clinical study for the treatment of hematological malignancies and solid tumors. The company has license agreements with Invivis Pharmaceuticals, Inc.; the Regents of the University of Minnesota; and the Ohio State University Innovation Foundation, as well as a co-development agreement with Leica Biosystems Newcastle Ltd. Arno Therapeutics, Inc. is based in Flemington, New Jersey.
Detailed Description


200 Route 31 NorthSuite 104Flemington, NJ 08822United States4 Employees



Phone: 862-703-7170

Fax: 908-237-0071

www.arnothera.com







Key Executives for Arno Therapeutics, Inc.




Dr. Alexander A. Zukiwski M.D.


      	Chief Executive Officer, President, Chief Medical Officer and Director
      


Age: 60
        

Total Annual Compensation: $543.8K








Dr. Stefan Proniuk Ph.D., MBA


      	Chief Development Officer
      


Age: 47
        

Total Annual Compensation: $298.3K





Compensation as of Fiscal Year 2015. 

Arno Therapeutics, Inc. Key Developments

Arno Therapeutics Files Form 15
Mar 30 17
Arno Therapeutics, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, par value $0.0001 per share under the Securities Exchange Act of 1934, as amended.


Arno Therapeutics Seeks Acquisitions
Jan 4 17
Arno Therapeutics, Inc. (OTCPK:ARNI) is seeking acquisitions and potential development opportunities to grow further.


Arno Therapeutics, Inc., Special/Extraordinary Shareholders Meeting, Dec 22, 2016
Nov 18 16
Arno Therapeutics, Inc., Special/Extraordinary Shareholders Meeting, Dec 22, 2016, at 09:00 US Eastern Standard Time. Location: 200 Route 31 North, Suite 104 Flemington, NJ 08822 United States Agenda: To authorize the amendment of certificate of incorporation to effect a combination (reverse split) of common stock at a ratio of 1-for-10; and to authorize the amendment of certificate of incorporation to reduce the number of authorized shares of common stock from 500,000,000 to 200,000,000.


Similar Private Companies By Industry



Company Name
Region



 20n Labs, Inc. United States 23andMe, Inc. United States 2C Tech Corporation, Inc. United States 3-V Biosciences, Inc. United States 3Bar Biologics Inc. United States




Recent Private Companies Transactions



TypeDate
Target





Private Placement

			      August 15, 2016
			    
--





Request Profile Update

















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



Most Searched Private Companies



Company Name
Geographic Region



 Lawyers Committee for Civil Rights Under Law United States NYC2012, Inc. United States The Advertising Council, Inc. United States Bertelsmann AG Europe Rush University United States













Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact Arno Therapeutics, Inc., please visit www.arnothera.com.  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close































Arno Therapeutics, Inc. - Product Pipeline Review - 2015

























 info@marketreportscenter.com
 +1-646-883-3044 (US) 24x7















LOGIN
SIGN UP














Facebook



Twitter



LinkedIn



Google +



MRC Blog



YouTube







Arno Therapeutics, Inc. - Product Pipeline Review - 2015

Home >> Pharmaceuticals >> Global Markets Direct >> Arno Therapeutics, Inc. - Product Pipeline Review - 2015



Report Details





Arno Therapeutics, Inc. - Product Pipeline Review - 2015







SKU
GMDSEP161509


Category
Pharmaceuticals


Publisher
Global Markets Direct


Pages
41


Published
Aug-15





SKUGMDSEP161509
CategoryPharmaceuticals
PublisherGlobal Markets Direct
Pages41
Published OnAug-15

Request Discount
Pay by Wire/Invoice





Description
Table of Content
List of Figures
Request Sample




Description
Arno Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Directs, Arno Therapeutics, Inc. - Product Pipeline Review - 2015, provides an overview of the Arno Therapeutics, Inc.s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Arno Therapeutics, Inc.s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Arno Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Arno Therapeutics, Inc.s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Arno Therapeutics, Inc.s pipeline products

Reasons to buy

- Evaluate Arno Therapeutics, Inc.s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Arno Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Arno Therapeutics, Inc.s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Arno Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arno Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Arno Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

News/Press Release

Precision Medicine: How the life science industry can improve outcomes through To achieve successful precision medicine at scale and to be able to offer it as an everyday treatment option, researchers in drug R&D need to better understand and manage the reams of unstructured dat...Read More
Regenerative Medicine Market to Hit $53 billion by 2021 The current regenerative medicine market is worth $18.9 billion globally, and will hit over $53 billion by 2021, as impact of Trump administration....Read More
7 Benefits of MicroneedlingMicroneedling: Hundreds of tiny pin pricks going into your skin might sound weird but it could just be the best thing that ever happened to your face....Read More



Table of Content
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Arno Therapeutics, Inc. Snapshot 4
Arno Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Arno Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Arno Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Arno Therapeutics, Inc. - Pipeline Products Glance 10
Arno Therapeutics, Inc. - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Phase I Products/Combination Treatment Modalities 11
Phase 0 Products/Combination Treatment Modalities 12
Arno Therapeutics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Arno Therapeutics, Inc. - Drug Profiles 14
onapristone ER 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AR-42 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
AR-12 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Arno Therapeutics, Inc. - Pipeline Analysis 20
Arno Therapeutics, Inc. - Pipeline Products by Target 20
Arno Therapeutics, Inc. - Pipeline Products by Route of Administration 21
Arno Therapeutics, Inc. - Pipeline Products by Molecule Type 22
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action 23
Arno Therapeutics, Inc. - Recent Pipeline Updates 24
Arno Therapeutics, Inc. - Dormant Projects 32
Arno Therapeutics, Inc. - Discontinued Pipeline Products 33
Discontinued Pipeline Product Profiles 33
AR-67 33
Arno Therapeutics, Inc. - Company Statement 34
Arno Therapeutics, Inc. - Locations And Subsidiaries 39
Head Office 39
Appendix 40
Methodology 40
Coverage 40
Secondary Research 40
Primary Research 40
Expert Panel Validation 40
Contact Us 40
Disclaimer 41


List of Figures
List of Tables
Arno Therapeutics, Inc., Key Information 4
Arno Therapeutics, Inc., Key Facts 4
Arno Therapeutics, Inc. - Pipeline by Indication, 2015 6
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Arno Therapeutics, Inc. - Phase II, 2015 10
Arno Therapeutics, Inc. - Phase I, 2015 11
Arno Therapeutics, Inc. - Phase 0, 2015 12
Arno Therapeutics, Inc. - Preclinical, 2015 13
Arno Therapeutics, Inc. - Pipeline by Target, 2015 20
Arno Therapeutics, Inc. - Pipeline by Route of Administration, 2015 21
Arno Therapeutics, Inc. - Pipeline by Molecule Type, 2015 22
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 23
Arno Therapeutics, Inc. - Recent Pipeline Updates, 2015 24
Arno Therapeutics, Inc. - Dormant Developmental Projects,2015 32
Arno Therapeutics, Inc. - Discontinued Pipeline Products, 2015 33
List of Figures
Arno Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 6
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2015 8
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 9
Arno Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 20
Arno Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 21
Arno Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 22
Arno Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 23







Please Select License Type






Single User Electronic PDF 
$ 1,500.00


Site User Electronic PDF 
$ 3,000.00


Enterprise Wide Electronic PDF 
$ 4,500.00



ADD TO CART

BUY NOW






Related Reports




 Global Oncology Market to 2023 - Robust Growth Driven by Rising Prevalence and Increased Uptake of Immune Checkpoint Inhibitors Urinary Incontinence - Pipeline Review, H2 2017 ICT Investment Trends in China: Enterprises initiatives inclined towards digitization fuelling ICT investments Global Pain Therapeutics Market to 2023 - Innovative New Products to Address Unmet Need within Chronic Pain and Migraine, and Tackle Opioid Abuse Global Veterinary Therapeutics Market Research Report 2017 










Request Sample






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Request Discount






Mr
Mrs
Ms
Dr






















Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND










Pay by Wire/Invoice






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
















Single User Electronic PDF
Site User Electronic PDF
Enterprise Wide Electronic PDF
CD ROM
Hard Copy














SEND










Request Quote






Mr
Mrs
Ms
Dr






























Afghanistan (+93)
Albania (+355)
Algeria (+213)
Andorra (+376)
Angola (+244)
Antigua and Barbuda (+-267)
Argentina (+54)
Armenia (+374)
Australia (+61)
Austria (+43)
Azerbaijan (+994)
Bahamas, The (+-241)
Bahrain (+973)
Bangladesh (+880)
Barbados (+-245)
Belarus (+375)
Belgium (+32)
Belize (+501)
Benin (+229)
Bhutan (+975)
Bolivia (+591)
Bosnia and Herzegovina (+387)
Botswana (+267)
Brazil (+55)
Brunei (+673)
Bulgaria (+359)
Burkina Faso (+226)
Burundi (+257)
Cambodia (+855)
Cameroon (+237)
Canada (+1)
Cape Verde (+238)
Central African Republic (+236)
Chad (+235)
Chile (+56)
China, People's Republic of (+86)
Colombia (+57)
Comoros (+269)
Congo, (Congo  Kinshasa) (+243)
Congo, (Congo  Brazzaville) (+242)
Costa Rica (+506)
Cote d'Ivoire (Ivory Coast) (+225)
Croatia (+385)
Cuba (+53)
Cyprus (+357)
Czech Republic (+420)
Denmark (+45)
Djibouti (+253)
Dominica (+-766)
Dominican Republic (++1-809 and 1-829)
Ecuador (+593)
Egypt (+20)
El Salvador (+503)
Equatorial Guinea (+240)
Eritrea (+291)
Estonia (+372)
Ethiopia (+251)
Fiji (+679)
Finland (+358)
France (+33)
Gabon (+241)
Gambia, The (+220)
Georgia (+995)
Germany (+49)
Ghana (+233)
Greece (+30)
Grenada (+-472)
Guatemala (+502)
Guinea (+224)
Guinea-Bissau (+245)
Guyana (+592)
Haiti (+509)
Honduras (+504)
Hungary (+36)
Iceland (+354)
India (+91)
Indonesia (+62)
Iran (+98)
Iraq (+964)
Ireland (+353)
Israel (+972)
Italy (+39)
Jamaica (+-875)
Japan (+81)
Jordan (+962)
Kazakhstan (+7)
Kenya (+254)
Kiribati (+686)
Korea, North (+850)
Korea, South (+82)
Kuwait (+965)
Kyrgyzstan (+996)
Laos (+856)
Latvia (+371)
Lebanon (+961)
Lesotho (+266)
Liberia (+231)
Libya (+218)
Liechtenstein (+423)
Lithuania (+370)
Luxembourg (+352)
Macedonia (+389)
Madagascar (+261)
Malawi (+265)
Malaysia (+60)
Maldives (+960)
Mali (+223)
Malta (+356)
Marshall Islands (+692)
Mauritania (+222)
Mauritius (+230)
Mexico (+52)
Micronesia (+691)
Moldova (+373)
Monaco (+377)
Mongolia (+976)
Montenegro (+382)
Morocco (+212)
Mozambique (+258)
Myanmar (Burma) (+95)
Namibia (+264)
Nauru (+674)
Nepal (+977)
Netherlands (+31)
New Zealand (+64)
Nicaragua (+505)
Niger (+227)
Nigeria (+234)
Norway (+47)
Oman (+968)
Pakistan (+92)
Palau (+680)
Panama (+507)
Papua New Guinea (+675)
Paraguay (+595)
Peru (+51)
Philippines (+63)
Poland (+48)
Portugal (+351)
Qatar (+974)
Romania (+40)
Russia (+7)
Rwanda (+250)
Saint Kitts and Nevis (+-868)
Saint Lucia (+-757)
Saint Vincent and the Grenadines (+-783)
Samoa (+685)
San Marino (+378)
Sao Tome and Principe (+239)
Saudi Arabia (+966)
Senegal (+221)
Serbia (+381)
Seychelles (+248)
Sierra Leone (+232)
Singapore (+65)
Slovakia (+421)
Slovenia (+386)
Solomon Islands (+677)
Somalia (+252)
South Africa (+27)
Spain (+34)
Sri Lanka (+94)
Sudan (+249)
Suriname (+597)
Swaziland (+268)
Sweden (+46)
Switzerland (+41)
Syria (+963)
Tajikistan (+992)
Tanzania (+255)
Thailand (+66)
Timor-Leste (East Timor) (+670)
Togo (+228)
Tonga (+676)
Trinidad and Tobago (+-867)
Tunisia (+216)
Turkey (+90)
Turkmenistan (+993)
Tuvalu (+688)
Uganda (+256)
Ukraine (+380)
United Arab Emirates (+971)
United Kingdom (+44)
United States (+1)
Uruguay (+598)
Uzbekistan (+998)
Vanuatu (+678)
Vatican City (+379)
Venezuela (+58)
Vietnam (+84)
Yemen (+967)
Zambia (+260)
Zimbabwe (+263)
Abkhazia (+995)
China, Republic of (Taiwan) (+886)
Nagorno-Karabakh (+277)
Northern Cyprus (+-302)
Pridnestrovie (Transnistria) (+-160)
Somaliland (+252)
South Ossetia (+995)
Ashmore and Cartier Islands (+)
Christmas Island (+61)
Cocos (Keeling) Islands (+61)
Coral Sea Islands (+)
Heard Island and McDonald Islands (+)
Norfolk Island (+672)
New Caledonia (+687)
French Polynesia (+689)
Mayotte (+262)
Saint Barthelemy (+590)
Saint Martin (+590)
Saint Pierre and Miquelon (+508)
Wallis and Futuna (+681)
French Southern and Antarctic Lands (+)
Clipperton Island (+)
Bouvet Island (+)
Cook Islands (+682)
Niue (+683)
Tokelau (+690)
Guernsey (+44)
Isle of Man (+44)
Jersey (+44)
Anguilla (+-263)
Bermuda (+-440)
British Indian Ocean Territory (+246)
British Sovereign Base Areas (+357)
British Virgin Islands (+-283)
Cayman Islands (+-344)
Falkland Islands (Islas Malvinas) (+500)
Gibraltar (+350)
Montserrat (+-663)
Pitcairn Islands (+)
Saint Helena (+290)
South Georgia & South Sandwich Islands (+)
Turks and Caicos Islands (+-648)
Northern Mariana Islands (+-669)
Puerto Rico (++1-787 and 1-939)
American Samoa (+-683)
Baker Island (+)
Guam (+-670)
Howland Island (+)
Jarvis Island (+)
Johnston Atoll (+)
Kingman Reef (+)
Midway Islands (+)
Navassa Island (+)
Palmyra Atoll (+)
U.S. Virgin Islands (+-339)
Wake Island (+)
Hong Kong (+852)
Macau (+853)
Faroe Islands (+298)
Greenland (+299)
French Guiana (+594)
Guadeloupe (+590)
Martinique (+596)
Reunion (+262)
Aland (+340)
Aruba (+297)
Netherlands Antilles (+599)
Svalbard (+47)
Ascension (+247)
Tristan da Cunha (+290)
Australian Antarctic Territory (+)
Ross Dependency (+)
Peter I Island (+)
Queen Maud Land (+)
British Antarctic Territory (+)
























SEND









Market Reports Center © Copyright 2017 All rights reserved.










































Arno Therapeutics, Inc. - Product Pipeline Review - 2015































| Compare 
About Us | 
Contact Us






Home
Research Category
Publisher List
Custom Research
Cart
Compare



Research Category
User Guide
Policies
Contact Us
About us
Site Map











Home > Market Research Report  > Pharmaceutical > Pharmaceutical Companies > Pharma Info









Market Research Report
Arno Therapeutics, Inc. - Product Pipeline Review - 2015



Published by
Global Markets Direct
Product code
251743


Published
August 31, 2015
Content info
41 Pages 


Price








USD 1500

PDF by E-mail (Single user license)





USD 3000

PDF by E-mail (Site license)





USD 4500

PDF by E-mail (Global license)
























Arno Therapeutics, Inc. - Product Pipeline Review - 2015



Published: August 31, 2015
Content info: 41 Pages














Description

Summary
Global Markets Direct's, 'Arno Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Arno Therapeutics, Inc.'s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Arno Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

 The report provides brief overview of Arno Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
 The report reviews current pipeline of Arno Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
 The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
 Special feature on out-licensed and partnered product portfolio
 The report summarizes all the dormant and discontinued pipeline projects
 Latest company statement
 Latest news and deals relating to the Arno Therapeutics, Inc.'s pipeline products

Reasons to buy

 Evaluate Arno Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
 Assess the growth potential of Arno Therapeutics, Inc. in its therapy areas of focus
 Identify new drug targets and therapeutic classes in the Arno Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
 Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
 Develop strategic initiatives by understanding the focus areas of Arno Therapeutics, Inc. and exploit collaboration and partnership opportunities
 Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
 Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arno Therapeutics, Inc.
 Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Explore the dormant and discontinued projects of Arno Therapeutics, Inc. and identify potential opportunities in those areas
 Avoid Intellectual Property Rights related issues




Table of Contents
Product Code: GMDHC07391CDBTable of Contents

Table of Contents 

List of Tables 
List of Figures 

Arno Therapeutics, Inc. Snapshot 

Arno Therapeutics, Inc. Overview 
Key Information 
Key Facts 

Arno Therapeutics, Inc. - Research and Development Overview 

Key Therapeutic Areas 

Arno Therapeutics, Inc. - Pipeline Review 

Pipeline Products by Stage of Development 
Pipeline Products - Monotherapy 

Arno Therapeutics, Inc. - Pipeline Products Glance 

Arno Therapeutics, Inc. - Clinical Stage Pipeline Products 

Phase II Products/Combination Treatment Modalities 
Phase I Products/Combination Treatment Modalities 
Phase 0 Products/Combination Treatment Modalities 

Arno Therapeutics, Inc. - Early Stage Pipeline Products 

Preclinical Products/Combination Treatment Modalities 


Arno Therapeutics, Inc. - Drug Profiles 

onapristone ER 

Product Description 
Mechanism of Action 
R&D Progress

AR-42 

Product Description 
Mechanism of Action 
R&D Progress

AR-12 

Product Description 
Mechanism of Action 
R&D Progress


Arno Therapeutics, Inc. - Pipeline Analysis 

Arno Therapeutics, Inc. - Pipeline Products by Target 
Arno Therapeutics, Inc. - Pipeline Products by Route of Administration 
Arno Therapeutics, Inc. - Pipeline Products by Molecule Type 
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action 

Arno Therapeutics, Inc. - Recent Pipeline Updates 
Arno Therapeutics, Inc. - Dormant Projects 
Arno Therapeutics, Inc. - Discontinued Pipeline Products 

Discontinued Pipeline Product Profiles 

AR-67 


Arno Therapeutics, Inc. - Company Statement 
Arno Therapeutics, Inc. - Locations And Subsidiaries 

Head Office 

Appendix 

Methodology 
Coverage 
Secondary Research 
Primary Research 
Expert Panel Validation 
Contact Us 
Disclaimer 


List of Tables

Arno Therapeutics, Inc., Key Information 
Arno Therapeutics, Inc., Key Facts 
Arno Therapeutics, Inc. - Pipeline by Indication, 2015 
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2015 
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 
Arno Therapeutics, Inc. - Phase II, 2015 
Arno Therapeutics, Inc. - Phase I, 2015 
Arno Therapeutics, Inc. - Phase 0, 2015 
Arno Therapeutics, Inc. - Preclinical, 2015 
Arno Therapeutics, Inc. - Pipeline by Target, 2015 
Arno Therapeutics, Inc. - Pipeline by Route of Administration, 2015 
Arno Therapeutics, Inc. - Pipeline by Molecule Type, 2015 
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 
Arno Therapeutics, Inc. - Recent Pipeline Updates, 2015 
Arno Therapeutics, Inc. - Dormant Developmental Projects,2015 
Arno Therapeutics, Inc. - Discontinued Pipeline Products, 2015 

List of Figures

Arno Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2015 
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 
Arno Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 
Arno Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 
Arno Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 
Arno Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 








Phone


Int'l: +1-860-674-8796
TollFree(US): +1-866-353-3335
Europe: +32-2-535-7543
Asia: +65-6223-2436


New for 2017 !

GII now purchases any market research reports from any publishers for you.  
			With noextra cost.
Contact us for more details.

FAQ


Delivery Time
User License
Payment Options
Compare Multiple Reports
















About
Contact
User Guide
Policies
Site Map



© Copyright 1997-2017, Global Information, Inc. All rights reserved.





  ARNI:OTC US Stock Quote - Arno Therapeutics Inc - Bloomberg Markets                     



     Error: Could not add to watchlist. X   + Watchlist  Arno Therapeutics Inc   ARNI:US   OTC US        0.05USD   0.01   28.71%     As of 8:10 PM EDT 7/21/2017     Open   0.05    Day Range   0.03 - 0.05    Volume   3,300    Previous Close   0.04    52Wk Range   0.01 - 0.89    1 Yr Return   -90.00%                   


                Before it's here, it's on the Bloomberg Terminal.
            

                Learn More
            

         Open   0.05    Day Range   0.03 - 0.05    Volume   3,300    Previous Close   0.04    52Wk Range   0.01 - 0.89    1 Yr Return   -90.00%    YTD Return   -72.19%    Current P/E Ratio (TTM)   -    Earnings per Share (USD) (TTM)   -0.34    Market Cap (m USD)   2.566    Shares Outstanding  (m)   49.350    Price/Sales (TTM)   -    Dividend Indicated Gross Yield   -        Sector Health Care   % Price Change -0.06%     Industry Pharmaceuticals, Biotechnology & Life Sciences   % Price Change +0.10%                    Related Videos  There are currently no related videos for this ticker. Please check back later.    Company News Press Releases   There are currently no news stories for this ticker. Please check back later.     7/10/2017   Prostate Cancer Pipeline H1 2017 Therapeutic Key Players 3-V Biosciences Inc, 4SC AG, Actinium Pharmaceuticals Inc and Advaxis     6/20/2017   Myelodysplastic Syndrome Pipeline Therapeutic Drugs and Companies Review H1 2017 Research Report Available at RnRMarketResearch     4/14/2017   H1 Pipeline on Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) for 2017 Market Therapeutics Growth and Assessment at     3/28/2017   Arno Therapeutics Announces Plan to Deregister its Common Stock    There are currently no press releases for this ticker. Please check back later.      Profile   Arno Therapeutics, Inc. is a development-stage company. The Company acquires, develops and commercializes products for the treatment of cancer. Arno seeks to acquire rights to novel, preclinical or early stage clinical oncology product candidates, primarily from academic and research institutions.    Address  4 Campus Drive, 2nd FloorParisppany, NJ 07054United States   Phone  1-862-703-7170   Website   www.arnothera.com     Executives Board Members    Alexander A Zukiwski "Alex"  CEO/Chief Medical Officer/IR    Stefan Proniuk  Chief Development Officer    David M Tanen  Secretary/Co-Founder     Show More         

Arno Therapeutics, Inc. - Product Pipeline Review - 2014 : ReportsnReports


























 



 Market Research Report 


Welcome Guest  |  
					Register/Login | 
					Contact Us | 
					About Us
  




+ 1 888 391 5441








Advanced Search










Home › 
                    
                        Pharmaceuticals › 
                     Report Detail 



 Arno Therapeutics, Inc. - Product Pipeline Review - 2014





						Published:  July 2014
						No. of Pages: 35

Price 
							
Single User License: US $ 1500
Corporate User License: US $ 4500
  
							


















Report Description
Table of Contents
 

Inquire Before Buying 










Global Markets Direct's, ?Arno Therapeutics, Inc. Product Pipeline Review 2014', provides an overview of the Arno Therapeutics, Inc.'s pharmaceutical research and development focus.This report provides comprehensive information on the current therapeutic developmental pipeline of Arno Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.ScopeThe report provides brief overview of Arno Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiariesThe report reviews current pipeline of Arno Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projectsThe report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestonesSpecial feature on out-licensed and partnered product portfolioThe report summarizes all the dormant and discontinued pipeline projectsLatest company statementLatest news and deals relating to the Arno Therapeutics, Inc.'s pipeline productsReasons to buyEvaluate Arno Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipelineAssess the growth potential of Arno Therapeutics, Inc. in its therapy areas of focusIdentify new drug targets and therapeutic classes in the Arno Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areasExploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gapsDevelop strategic initiatives by understanding the focus areas of Arno Therapeutics, Inc. and exploit collaboration and partnership opportunitiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantagePlan mergers and acquisitions effectively by identifying the most promising pipeline of Arno Therapeutics, Inc.Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeExplore the dormant and discontinued projects of Arno Therapeutics, Inc. and identify potential opportunities in those areasAvoid Intellectual Property Rights related issues





                               Arno Therapeutics, Inc. - Product Pipeline Review - 2014                            


Table of ContentsTable of Contents 2List of Tables 3List of Figures 3Arno Therapeutics, Inc. Snapshot 4Arno Therapeutics, Inc. Overview 4Key Information 4Key Facts 4Arno Therapeutics, Inc. - Research and Development Overview 5Key Therapeutic Areas 5Arno Therapeutics, Inc. - Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products - Monotherapy 9Arno Therapeutics, Inc. - Pipeline Products Glance 10Arno Therapeutics, Inc. - Clinical Stage Pipeline Products 10Phase I Products/Combination Treatment Modalities 10Arno Therapeutics, Inc. - Early Stage Pipeline Products 11Preclinical Products/Combination Treatment Modalities 11Arno Therapeutics, Inc. - Drug Profiles 12AR-42 12Product Description 12Mechanism of Action 12R&D Progress 12onapristone ER 14Product Description 14Mechanism of Action 14R&D Progress 14AR-12 16Product Description 16Mechanism of Action 16R&D Progress 16Arno Therapeutics, Inc. - Pipeline Analysis 18Arno Therapeutics, Inc. - Pipeline Products by Target 18Arno Therapeutics, Inc. - Pipeline Products by Route of Administration 19Arno Therapeutics, Inc. - Pipeline Products by Molecule Type 20Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action 21Arno Therapeutics, Inc. - Recent Pipeline Updates 22Arno Therapeutics, Inc. - Dormant Projects 27Arno Therapeutics, Inc. - Discontinued Pipeline Products 28Discontinued Pipeline Product Profiles 28AR-67 28Arno Therapeutics, Inc. - Company Statement 29Arno Therapeutics, Inc. - Locations And Subsidiaries 33Head Office 33Appendix 34Methodology 34Coverage 34Secondary Research 34Primary Research 34Expert Panel Validation 34Contact Us 35Disclaimer 35List of TablesArno Therapeutics, Inc., Key Information 4Arno Therapeutics, Inc., Key Facts 4Arno Therapeutics, Inc. - Pipeline by Indication, 2014 7Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9Arno Therapeutics, Inc. - Phase I, 2014 10Arno Therapeutics, Inc. - Preclinical, 2014 11Arno Therapeutics, Inc. - Pipeline by Target, 2014 18Arno Therapeutics, Inc. - Pipeline by Route of Administration, 2014 19Arno Therapeutics, Inc. - Pipeline by Molecule Type, 2014 20Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 21Arno Therapeutics, Inc. - Recent Pipeline Updates, 2014 22Arno Therapeutics, Inc. - Dormant Developmental Projects,2014 27Arno Therapeutics, Inc. - Discontinued Pipeline Products, 2014 28List of FiguresArno Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9Arno Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 18Arno Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 19Arno Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 20Arno Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21




 

Published By: 
                            Global Markets Direct 

Product Code:
                            Global Markets Direct8987 







                        Did you find what you are/were looking for
                        ?
                        If not, read below and browse through other relevant pages for similar market research
                        reports OR get in touch with us through the form/contact info in your right navigation
                        panel and well share relevant market report titles for you to explore.
					


                            Related Reports:
                        





 Europe Veterinary Vaccine Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						Vaccines are products designed to trigger protective immune responses and prepare the immune system to fight future infections from disease-causing agents. Vaccines stimulate the immune systems production of antibodies that identify and destroy dis...  
 Europe Injectable Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						"The injectable anticoagulants include low molecular weight heparin (LMWH) agents (dalteparin [Fragmin?], enoxaparin [Lovenox?]) and factor Xa inhibitors (fondaparinux [Arixtra?]).

In general, the injectable anticoagulants are Food and Drug Admini...  
 Europe Ginseng Extract Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						Ginseng is a plant characterized by a fleshy root and a single stalk with green oval-shaped leaves. It is a perennial plant that can live more than a century. Ginseng is typically derived from the root of this plant. As an herbal supplement, the extr...  
 Europe Dunaliella Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						Dunaliella is a genus of the algae family Dunaliellaceae. It is widely distributed in natural habitat ranging from ocean and lakes of saturated brine. Dunaliella is unicellular bi-flagellate, naked, green-alga with ovoid in shape, without cell wall, ...  
 Europe Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						Anticoagulants, commonly referred to as blood thinners, are substances that prevent or reduce coagulation of blood, prolonging the clotting time. Some of them occur naturally in blood-eating animals such as leeches and mosquitoes, where they help kee...  
 North America Physiological Saline Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						Physiological Saline is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds, help remove contact lenses, and help with dry eyes. By injection into a vein it is used to tr...  
 Global Newcastle Disease Vaccine Market by Manufacturers, Countries, Type and Application, Forecast to 2022						
						"Newcastle disease is a contagious viral bird disease affecting many domestic and wild avian species; it is transmissible to humans.

Newcastle disease can be controlled by the use of vaccines. There are many Newcastle disease vaccines suitable for...  
 Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022						
						This report splits Onychomycosis (Tinea Unguium) Drug by Product Drug Form, by Product Usage Type. This shares the history data information from 2012 to 2016, and forecast from 2017 to 2022.

And this report mainly introduces volume and value marke...  
 2017-2022 United States Vaginal Pessary Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% fro...  
 2017-2022 United States Tuberculin Market Report (Status and Outlook)						
						"This report will be delivered in 2-3 business days after the order is placed."

The Tuberculin market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 201...  









 







  
   



Why ReportsnReports.com?

500,000 market research reports and growing.
Top Fortune 500 Organizations trust us for research data.
24/7 support on call as well as emails.
Your Details are safe with us.
Free support for your research requirements.
Report Delivery: Email
Delivery Time:
                            
Upto 24 hrs - working days
Upto 48 hrs max - weekends and public holidays






Research Support / Custom Research
                    If this business study does not have the data and information analysis you need,
                    contact us with your research requirements. We explore available market research
                    reports to map your needs and share report titles with you. Alternatively, we can
                    also offer custom research that suits your budget and timelines. Share your information
                    requirements here.



                        Connect With Us





 









































Email: sales@reportsandreports.com
Call : + 1 888 391 5441 


 



Home
Category
Publisher
Country
Latest Reports
Markets
Discounted Reports
Upcoming Reports
Contact Us



Subscription Option



                                Using our subscription option, you get access to market research reports and industry data of  Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.


More about our Subscription option 




Report Alerts

Get Email alerts about market research reports from industries and publishers of
							your interest:







Please Enter a Valid Email ID
Thank you! You have successfully subscribed to our Report Alerts!






 







 Avail upto 25% Discount on below Publisher Reports.

Technavio
Azoth Analytics







					© 2017 ReportsnReports. All rights reserved. Disclamer. 
						Privacy Policy , Terms and Conditions
					| Our Market Research Blog | Sitemap

Feeds: RSS | Latest Reports












    ARNI Key Statistics - Arno Therapeutics Inc. Financial Ratios - MarketWatch




































Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot


















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































Arno Therapeutics Inc.

                  OTC: ARNI
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

Arno Therapeutics Inc.



Market closed
 --Quotes are delayed by 20 min
Jul 21, 2017, 5:20 p.m.


ARNI

/quotes/zigman/24159376/delayed


$
0.05




Change

+0.01
+28.71%

Volume
Volume 3,300
Quotes are delayed by 20 min








/quotes/zigman/24159376/delayed
Previous close

$
			0.04
		


$
				0.05
			
Change

+0.01
+28.71%





Day low
Day high
$0.03
$0.05










52 week low
52 week high

            $0.01
        

            $0.89
        

















			Company Description 


			Arno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. It develops pre-clinical and clinical-stage product under the following brands: Onapristone, AR-42, and AR-12. Th...
		


                Arno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. It develops pre-clinical and clinical-stage product under the following brands: Onapristone, AR-42, and AR-12. The company was founded by Peter Morgan Kash, David M. Tanen, and Joshua A. Kazam in March 2000 and is headquartered in Flemington, NJ.
            




Valuation

P/E Current
-0.09


P/E Ratio (with extraordinary items)
-0.17


Enterprise Value to EBITDA
-0.34


Total Debt to Enterprise Value
0.23

Efficiency

Income Per Employee
-2,876,991.00

Liquidity

Current Ratio
0.08


Quick Ratio
0.08


Cash Ratio
0.02



Profitability

Return on Assets
-267.35

Capital Structure

Total Debt to Total Assets
580.73





      Officers and Executives
    



Name
Age
Officer Since
Title





Dr. Alexander A. Zukiwski 
59
2011
CEO, Principal Financial Officer & Director





Insider Actions


 – Purchase

 – Sale
1
 – Number of Transactions











{"OrganizationDocuments":[{"Documents":[{"document":[{"reportDateGroup":[{"reportDate":"2011-06-09","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-05-17","tradeTypeGroup":[{"numTransactions":"3","tradeType":"D"},{"numTransactions":"1","tradeType":"A"}]},{"reportDate":"2011-05-16","tradeTypeGroup":[{"numTransactions":"2","tradeType":"D"},{"numTransactions":"8","tradeType":"A"}]},{"reportDate":"2011-05-13","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-12","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-11","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-05-02","tradeTypeGroup":[{"numTransactions":"1","tradeType":"D"}]},{"reportDate":"2011-03-10","tradeTypeGroup":[{"numTransactions":"5","tradeType":"A"}]},{"reportDate":"2011-02-17","tradeTypeGroup":[{"numTransactions":"4","tradeType":"D"},{"numTransactions":"2","tradeType":"A"}]},{"reportDate":"2011-02-15","tradeTypeGroup":[{"numTransactions":"8","tradeType":"A"},{"numTransactions":"1","tradeType":"D"}]}]}]}]}]}


Date
Name
Shares
Transaction
Value





10/03/2016

David M. Tanen 
Secretary; Director

142,857


 
Acquisition at $0 per share.


0


08/15/2016

Arie S. Belldegrun 
Director

714,285


 
Acquisition at $0 per share.


0


08/15/2016

Pontifax Management Co. Ltd.                            
Director

102,100


 
Acquisition at $0 per share.


0


08/15/2016

Pontifax Management Co. Ltd.                            
Director

263,017


 
Acquisition at $0 per share.


0


08/15/2016

Pontifax Management Co. Ltd.                            
Director

349,168


 
Acquisition at $0 per share.


0


01/12/2016

David M. Tanen 
Secretary; Director

362,015


 
Acquisition at $0.35 per share.


126,705


01/12/2016

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

144,806


 
Acquisition at $0.35 per share.


50,682


10/29/2013

Commercial Street Capital LLC                            


41,666


 
Award at $2.4 per share.


99,998


10/29/2013

Arie S. Belldegrun 
Director

6,666


 
Award at $2.4 per share.


15,998


10/29/2013

Arie S. Belldegrun 
Director

5,000


 
Award at $2.4 per share.


12,000


10/29/2013

Arie S. Belldegrun 
Director

11,666


 
Award at $2.4 per share.


27,998


10/29/2013

Arie S. Belldegrun 
Director

10,000


 
Award at $2.4 per share.


24,000


10/29/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

5,000


 
Award at $2.4 per share.


12,000


10/29/2013

Glenn R. Mattes                            
President & CEO; Director

1,666


 
Award at $2.4 per share.


3,998


10/29/2013

Stefan Proniuk 
Chief Development Officer

666


 
Award at $2.4 per share.


1,598


10/29/2013

Commercial Street Capital LLC                            


687,500


 
Acquisition at $0 per share.


0


10/29/2013

Arie S. Belldegrun 
Director

83,332


 
Acquisition at $0 per share.


0


10/29/2013

Arie S. Belldegrun 
Director

187,500


 
Acquisition at $0 per share.


0


10/29/2013

Arie S. Belldegrun 
Director

104,166


 
Acquisition at $0 per share.


0


10/29/2013

Arie S. Belldegrun 
Director

104,166


 
Acquisition at $0 per share.


0


10/29/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

41,666


 
Acquisition at $0 per share.


0


10/29/2013

Glenn R. Mattes                            
President & CEO; Director

20,833


 
Acquisition at $0 per share.


0


10/29/2013

William F. Hamilton 
Director

20,833


 
Acquisition at $0 per share.


0


10/29/2013

Commercial Street Capital LLC                            


555,440


 
Derivative/Non-derivative trans. at $2.4 per share.


1,333,056


10/29/2013

Arie S. Belldegrun 
Director

88,871


 
Derivative/Non-derivative trans. at $2.4 per share.


213,290


10/29/2013

Arie S. Belldegrun 
Director

66,652


 
Derivative/Non-derivative trans. at $2.4 per share.


159,964


10/29/2013

Arie S. Belldegrun 
Director

155,523


 
Derivative/Non-derivative trans. at $2.4 per share.


373,255


10/29/2013

Arie S. Belldegrun 
Director

133,305


 
Derivative/Non-derivative trans. at $2.4 per share.


319,932


10/29/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

66,652


 
Derivative/Non-derivative trans. at $2.4 per share.


159,964


10/29/2013

Glenn R. Mattes                            
President & CEO; Director

22,218


 
Derivative/Non-derivative trans. at $2.4 per share.


53,323


10/29/2013

Stefan Proniuk 
Chief Development Officer

8,887


 
Derivative/Non-derivative trans. at $2.4 per share.


21,328


10/04/2013

Wexford Capital LP                            


325


 
Disposition at $0.48 per share.


156


05/28/2013

Commercial Street Capital LLC                            


80,556


 



24,166


05/28/2013

Arie S. Belldegrun 
Director

12,889


 



3,866


05/28/2013

Arie S. Belldegrun 
Director

9,667


 



2,900


05/28/2013

Arie S. Belldegrun 
Director

22,556


 



6,766


05/28/2013

Arie S. Belldegrun 
Director

19,333


 



5,799


05/28/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

9,667


 



2,900


05/28/2013

Glenn R. Mattes                            
President & CEO; Director

3,222


 



966


05/28/2013

Stefan Proniuk 
Chief Development Officer

1,289


 



386


05/22/2013

Ralph H. Thurman 
Director

2,500


 
Acquisition at $0.5 per share.


1,250


05/21/2013

Ralph H. Thurman 
Director

7,500


 
Acquisition at $0.5 per share.


3,750


04/29/2013

Commercial Street Capital LLC                            


83,333


 



24,999


04/29/2013

Arie S. Belldegrun 
Director

13,333


 



3,999


04/29/2013

Arie S. Belldegrun 
Director

10,000


 



3,000


04/29/2013

Arie S. Belldegrun 
Director

23,333


 



6,999


04/29/2013

Arie S. Belldegrun 
Director

20,000


 



6,000


04/29/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

10,000


 



3,000


04/29/2013

Glenn R. Mattes                            
President & CEO; Director

3,333


 



999


04/29/2013

Stefan Proniuk 
Chief Development Officer

1,333


 



399


03/27/2013

Commercial Street Capital LLC                            


83,333


 



24,999


03/27/2013

Arie S. Belldegrun 
Director

13,333


 



3,999


03/27/2013

Arie S. Belldegrun 
Director

10,000


 



3,000


03/27/2013

Arie S. Belldegrun 
Director

23,333


 



6,999


03/27/2013

Arie S. Belldegrun 
Director

20,000


 



6,000


03/27/2013

Alexander A. Zukiwski 
Chief Executive Officer & CMO; Director

10,000


 



3,000


03/27/2013

Glenn R. Mattes                            
President & CEO; Director

3,333


 



999


03/27/2013

Stefan Proniuk 
Chief Development Officer

1,333


 



399








/news/latest/company/us/arni

      MarketWatch News on ARNI
    
No News currently available for ARNI





/news/nonmarketwatch/company/us/arni

      Other News on ARNI
    





Tracking George Soros's Portfolio - Q4 2016 Update

9:56 a.m. Feb. 17, 2017
 - Seeking Alpha




 10-Q: ARNO THERAPEUTICS, INC
5:19 p.m. Nov. 14, 2016
 - Edgar Online -  (EDG = 10Q, 10K)




 10-Q: ARNO THERAPEUTICS, INC
5:12 p.m. Aug. 22, 2016
 - Edgar Online -  (EDG = 10Q, 10K)





Arno Therapeutics to raise $2.8M via direct placement

9:27 a.m. Aug. 16, 2016
 - Seeking Alpha





Past Failures Set Arno Therapeutics Up For Success.

9:59 a.m. Jan. 28, 2016
 - Seeking Alpha





Insiders Roundup: Top Buys, Sales of the Week

1:43 p.m. Jan. 15, 2016
 - GuruFocus.com





Opko Health: Why Recent Weakness Represents A Golden Buying Opportunity

8:10 a.m. July 24, 2015
 - Seeking Alpha





Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015

8:31 a.m. May 4, 2015
 - Seeking Alpha





Biotech Weekly: Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015

8:31 a.m. May 4, 2015
 - Seeking Alpha





Arno Therapeutics: A Likely Acquisition For Opko

2:54 p.m. Dec. 17, 2013
 - Seeking Alpha




 Hedge Funds Raise Large-Cap Holdings
3:38 p.m. Feb. 25, 2010
 - The Wall Street Journal Interactive Edition














At a Glance

Arno Therapeutics, Inc.
200 Route 31 North
Suite 104

Flemington, New Jersey 08822




Phone
1 8627037170


Industry
Biotechnology


Sector
Health Care/Life Sciences


Fiscal Year-end
12/2016


View SEC Filings




Revenue
N/A


Net Income
$-11.51M


Employees

        4.00


Annual Report for ARNI











/news/pressrelease/company/us/arni

      Press Releases on ARNI
    
No News currently available for ARNI







Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




2:45 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15

























































Arno Therapeutics, Inc. - Product Pipeline Review - 2014 - RnR Market Research












































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 
 
﻿  Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.com

On the Web       

Related Markets
BiotechnologyBiomaterialsBiomarkersStem CellDrug DiscoveryIndustrial BiotechnologyWound CareEnzymeMicroarrayBiopharmaceuticalCell Culture
Related Market ReportsArno Therapeutics, Inc. - Product Pipeline Review - 2015



Home  
 > Life Sciences > Pharmaceuticals > Report Detail


 

Arno Therapeutics, Inc. - Product Pipeline Review - 2014


Publisher Name :
Global Markets Direct
 Date: 10-Jul-2014
No. of pages: 35







Price:

Single User License: US $1500
Corporate User License: US $4500






 
Report DescriptionTable of ContentNews & BlogOther ReportsOur Offerings




Global Markets Direct's, Arno Therapeutics, Inc. Product Pipeline Review 2014', provides an overview of the Arno Therapeutics, Inc.'s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Arno Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope

The report provides brief overview of Arno Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
The report reviews current pipeline of Arno Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
Special feature on out-licensed and partnered product portfolio
The report summarizes all the dormant and discontinued pipeline projects
Latest company statement
Latest news and deals relating to the Arno Therapeutics, Inc.'s pipeline products

Reasons to buy

Evaluate Arno Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
Assess the growth potential of Arno Therapeutics, Inc. in its therapy areas of focus
Identify new drug targets and therapeutic classes in the Arno Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
Develop strategic initiatives by understanding the focus areas of Arno Therapeutics, Inc. and exploit collaboration and partnership opportunities
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Plan mergers and acquisitions effectively by identifying the most promising pipeline of Arno Therapeutics, Inc.
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Explore the dormant and discontinued projects of Arno Therapeutics, Inc. and identify potential opportunities in those areas
Avoid Intellectual Property Rights related issues



Arno Therapeutics, Inc. - Product Pipeline Review - 2014
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 3
Arno Therapeutics, Inc. Snapshot 4
Arno Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Arno Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Arno Therapeutics, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Arno Therapeutics, Inc. - Pipeline Products Glance 10
Arno Therapeutics, Inc. - Clinical Stage Pipeline Products 10
Phase I Products/Combination Treatment Modalities 10
Arno Therapeutics, Inc. - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Arno Therapeutics, Inc. - Drug Profiles 12
AR-42 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
onapristone ER 14
Product Description 14
Mechanism of Action 14
R&D Progress 14
AR-12 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Arno Therapeutics, Inc. - Pipeline Analysis 18
Arno Therapeutics, Inc. - Pipeline Products by Target 18
Arno Therapeutics, Inc. - Pipeline Products by Route of Administration 19
Arno Therapeutics, Inc. - Pipeline Products by Molecule Type 20
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action 21
Arno Therapeutics, Inc. - Recent Pipeline Updates 22
Arno Therapeutics, Inc. - Dormant Projects 27
Arno Therapeutics, Inc. - Discontinued Pipeline Products 28
Discontinued Pipeline Product Profiles 28
AR-67 28
Arno Therapeutics, Inc. - Company Statement 29
Arno Therapeutics, Inc. - Locations And Subsidiaries 33
Head Office 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 35
Disclaimer 35
List of Tables
Arno Therapeutics, Inc., Key Information 4
Arno Therapeutics, Inc., Key Facts 4
Arno Therapeutics, Inc. - Pipeline by Indication, 2014 7
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9
Arno Therapeutics, Inc. - Phase I, 2014 10
Arno Therapeutics, Inc. - Preclinical, 2014 11
Arno Therapeutics, Inc. - Pipeline by Target, 2014 18
Arno Therapeutics, Inc. - Pipeline by Route of Administration, 2014 19
Arno Therapeutics, Inc. - Pipeline by Molecule Type, 2014 20
Arno Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2014 21
Arno Therapeutics, Inc. - Recent Pipeline Updates, 2014 22
Arno Therapeutics, Inc. - Dormant Developmental Projects,2014 27
Arno Therapeutics, Inc. - Discontinued Pipeline Products, 2014 28
List of Figures
Arno Therapeutics, Inc. - Pipeline by Top 10 Indication, 2014 6
Arno Therapeutics, Inc. - Pipeline by Stage of Development, 2014 8
Arno Therapeutics, Inc. - Monotherapy Products in Pipeline, 2014 9
Arno Therapeutics, Inc. - Pipeline by Top 10 Target, 2014 18
Arno Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2014 19
Arno Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2014 20
Arno Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2014 21




High-speed Data Transmission And High Volume Needs Propel Fiber Optic Connectors Market Fiber optic connectors are a substantial fragment of the global telecommunication industry. Optical fibers are joined using fiber optic connectors, which allow the light conduction between two consecutive optical fibers. An additional im…Extensive Use of Digital Technologies for Diagnostic Applications To Boost Global Optical Imaging Market  The global optical imaging system market is predicted to reach US$ 3 billion by 2024. It is expected to grow at a stable rate and will post a CAGR of more than 8% in the coming years. The growing market infiltration of digital …Foremost Trends In Global Pet Care Market The global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments. It is estimated that the global pet care market will grow at a CAGR o…China To Review Its Food Security Laws  China has arisen as the globe’s firmest developing economy. In addition, China brags about the biggest population pool in the world. In recent times, the one child policy in the republic was terminated. This is anticipated to upsur…Improving Standards Of Living To Boost Global Consumer Durables Market  Consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time. Profits in the consumer durables sector were most profoundly…

2017-2022 Philippines Vaginal Pessary Market Report (Status and Outlook)

Published:  21-Jul-2017        Price: US 3360 Onwards        Pages: 111 
"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Philippines, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In Malaysia market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac ......

2017-2022 United States Vaginal Pessary Market Report (Status and Outlook)

Published:  21-Jul-2017        Price: US 3360 Onwards        Pages: 111 
"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in United States, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In United States market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
......

North America Physiological Saline Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Published:  21-Jul-2017        Price: US 4480 Onwards        Pages: 117 
Physiological Saline is a mixture of sodium chloride in water and has a number of uses in medicine. Applied to the affected area it is used to clean wounds, help remove contact lenses, and help with dry eyes. By injection into a vein it is used to treat dehydration such as from gastroenteritis and diabetic ketoacidosis. It is also used to dilute other medications to be given by injection.

Scope of the Report:

This report focuses on the Physiological Saline in North ......

Europe Dunaliella Market by Manufacturers, Countries, Type and Application, Forecast to 2022

Published:  21-Jul-2017        Price: US 4480 Onwards        Pages: 121 
Dunaliella is a genus of the algae family Dunaliellaceae. It is widely distributed in natural habitat ranging from ocean and lakes of saturated brine. Dunaliella is unicellular bi-flagellate, naked, green-alga with ovoid in shape, without cell wall, 4-10 µm wide and 6-15 µm long. It is the plant containing the highest amount of carotenoids, including alpha-carotene, beta-carotene, zeaxanthin, lutein, cryptoxanthin and lycopene, and abundant unsaturated fatty acid, especially linolenic acid. Henc......

2017 Top 5 Vaginal Pessary Manufacturers in North America, Europe, Asia-Pacific, South America, Middle East and Africa

Published:  21-Jul-2017        Price: US 4960 Onwards        Pages: 163 
"This report will be delivered in 2-3 business days after the order is placed."

The Global Vaginal Pessary market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

This report studies Vaginal Pessary in Global market, especially in North America, Europe, Asia-Pacific, South America, Middle East and Africa, focuses on the top 5 Vaginal Pessary Players in each reg......

2017-2022 China Vaginal Pessary Market Report (Status and Outlook)

Published:  21-Jul-2017        Price: US 3360 Onwards        Pages: 111 
"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in China, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In China market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical......

2017-2022 Global Top Countries Vaginal Pessary Market Report

Published:  21-Jul-2017        Price: US 4960 Onwards        Pages: 163 
"This report will be delivered in 2-3 business days after the order is placed."

The Global Vaginal Pessary market size will be XX million (USD) in 2022, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

This report studies Vaginal Pessary in Global market, especially in United States, Canada, Mexico, Germany, France, UK, Italy, Russia, China, Japan, India, Korea, Southeast Asia, Australia, Brazil, Mi......

2017-2022 India Vaginal Pessary Market Report (Status and Outlook)

Published:  21-Jul-2017        Price: US 3360 Onwards        Pages: 111 
"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in India, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In India market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical......

2017-2022 Japan Vaginal Pessary Market Report (Status and Outlook)

Published:  21-Jul-2017        Price: US 3360 Onwards        Pages: 111 
"This report will be delivered in 2-3 business days after the order is placed."

The Vaginal Pessary market size will be XX million (USD) in 2022 in Japan, from the XX million (USD) in 2016, with a CAGR (Compound Annual Growth Rate) XX% from 2016 to 2022.

In Japan market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical......


SERVICES

Value for Money
We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.

Ever Growing Inventory
Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.

One Stop Solution
Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.

Dedicated Client Engagement
Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.

Saving Time and Efforts
Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.

Payment Flexibility
Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.

Post-Purchase Research Support
Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements.
Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )

Ad Hoc
Pay - as - you - go / Bucket Subscriptions
Fixed Cost for #of reports
Customize / Personalize as per your needs


















 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio













Pharmaceuticals Market Research Reports on Market Size and Competitive Analysis











































Advanced search


1 888 391 5441

sales@rnrmarketresearch.com


Search Market Research Reports






 Market Research Assistance+ 1-888-391-5441sales@rnrmarketresearch.comOn the Web       

Refine ResultBy DateLast MonthLast 3 MonthsLast 6 MonthsLast YearLast 2 Years
By Price< $1000$1000-$2500$2501-$4000$4001-$5500$5501-$7500$7501-$9000>$9000





Home
  >  Life Sciences  >  Pharmaceuticals 




Pharmaceuticals Market Research Reports 

 

The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this industry. The pharmaceutical market, valued as a multi-billion dollar market, is undoubtedly the largest revenue generator for the life sciences industry.

The pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications. The largest segment, the market for cardiovascular drugs, records huge sales every year. The rising world population, rap...View More
The global pharmaceutical market has persistently experienced significant growth due to the ever-increasing demand for novel and more effective drugs. The reasons for this steady increase in the demand for drugs worldwide can be attributed to population growth, newer and more complex disease conditions, ageing population, and the increased prevalence of chronic and infectious diseases, some of which still remain incurable and fatal. Such numerous unmet needs and high demand rates have triggered the boost in R&D investments by key industry sectors, greatly driving the growth of this industry. The pharmaceutical market, valued as a multi-billion dollar market, is undoubtedly the largest revenue generator for the life sciences industry.

The pharmaceutical industry can be divided into numerous market segments based on the different therapeutic areas and applications. The largest segment, the market for cardiovascular drugs, records huge sales every year. The rising world population, rapid ageing of the same, and an increased prevalence of diseases are the major factors driving growth of this industry. The recent breakthroughs in proteomics and genomics have led to the development of modernized approaches to drug discovery and development in the industry, for the possibility of newer, advanced, and more sophisticated therapies and drugs. Developments in biotechnology research have led to introduction of advanced therapies involving biopharmaceuticals, regenerative medicine, stem cells, etc. These new age therapies and products have caused ease of treatment procedures and enabled speedy recovery from various disorders. Technological growth in such interdisciplinary fields has opened up new arenas in drug discovery, drug delivery, and life sciences research.View Less


TherapeuticsDiseases & treatmentClinical TrialDietary SupplementsBiopharmaceuticalsPharmaceutical PackagingPain ManagementPandemic VaccineBiosimilarPharmaceutical DistributionOver The Counter (OTC) DrugAnesthesia DrugsCancer VaccinePharmaceutical TechnologyRadiopharmaceuticalPrescription DrugsPharmaceutical DetailingClinical Nutrition

Pharmaceuticals Market Research Reports 

Titlepublishedprice

Europe Injectable Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022By Global Info Research"...... is and/or treatment of venous thromboembolism."

Scope of the Report:

This report focuses on the Injectable Anticoagulants in Europe market, especially in Germany, UK, France, Russia, and Italy. This report categorizes th......"21-Jul-2017$4480

Europe Ginseng Extract Market by Manufacturers, Countries, Type and Application, Forecast to 2022By Global Info Research"...... ving anti-inflammatory, anti-cancer, and antioxidant properties. It is also used in the homeopathic treatment of conditions, including depression, stress, low libido, and Attention Deficit Hyperactivity Disorder (ADHD).

Scope of the Re......"21-Jul-2017$4480

Europe Dunaliella Market by Manufacturers, Countries, Type and Application, Forecast to 2022By Global Info Research"...... ntaining the highest amount of carotenoids, including alpha-carotene, beta-carotene, zeaxanthin, lutein, cryptoxanthin and lycopene, and abundant unsaturated fatty acid, especially linolenic acid. Hence, it is university acknowledged of the commercia......"21-Jul-2017$4480

Europe Anticoagulants Market by Manufacturers, Countries, Type and Application, Forecast to 2022By Global Info Research"...... mal to obtain some blood. As a class of medications, anticoagulants are used in therapy for thrombotic disorders. Oral anticoagulants (OACs) are taken by many people in pill or tablet form, and various intravenous anticoagulant dosage forms are used ......"21-Jul-2017$4480

North America Physiological Saline Market by Manufacturers, Countries, Type and Application, Forecast to 2022By Global Info Research"...... diabetic ketoacidosis. It is also used to dilute other medications to be given by injection.

Scope of the Report:

This report focuses on the Physiological Saline in North America market, especially in United States, Cana......"21-Jul-2017$4480

Global Onychomycosis (Tinea Unguium) Drug Detailed Analysis Report 2017-2022By QYResearch Group"...... oduct type, by consumers and also their price change details. As a Detailed Analysis report, it covers all details inside analysis and opinion in Onychomycosis (Tinea Unguium) Drug industry.

This report focus Global market, it covers d......"21-Jul-2017$3250

2017-2022 United States Vaginal Pessary Market Report (Status and Outlook)By LP Information INC"...... >

In United States market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical
Medesign
Smi......"21-Jul-2017$3360

2017-2022 United States Tuberculin Market Report (Status and Outlook)By LP Information INC"...... r />
In United States market, the top players include
Sanofi Pasteur
Zoetis
Par Sterile
SSI
Japan BCG
Thermo Fisher
Sanroad Biological
CNBG......"21-Jul-2017$3360

2017-2022 Philippines Vaginal Pessary Market Report (Status and Outlook)By LP Information INC"...... 

In Malaysia market, the top players include
CooperSurgical
MedGyn
Personal Medical Corp
Integra LifeSciences
Panpac Medical
Medesign
Smiths Med......"21-Jul-2017$3360

2017-2022 Philippines Tuberculin Market Report (Status and Outlook)By LP Information INC"...... />
In Malaysia market, the top players include
Sanofi Pasteur
Zoetis
Par Sterile
SSI
Japan BCG
Thermo Fisher
Sanroad Biological
CNBG......"21-Jul-2017$3360
 
1 | 2 | 3 | 4 | 5 | 6 | 7 | ...3372 | 3373next »

 








 Avail upto 25% Discount on below Publisher Reports.
   
Azoth Analytics 
Technavio













ARNI Stock Price - Arno Therapeutics Inc. Stock Quote (U.S.: OTC) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,580.07


-31.71


-0.15%











S&P 500

2,472.54


-0.91


-0.04%











Nasdaq

6,387.75


-2.25


-0.04%











GlobalDow

2,831.96


-1.24


-0.04%











Gold

1,258.90


-2.10


-0.17%











Oil

45.79


0.02


0.04%

















S&P 500 Movers(%)



CTAS 
9.2




COF 
8.6




ETFC 
5.1




SYF 
4.5






HP
-5.5




ISRG
-4.6




HBAN
-4.4




CHK
-3.1














Latest NewsAll Times Eastern








2:27a

Reckitt Benckiser profit rises on reduced costs



2:14a

Chinese regulator tells insurers to shape up



2:13a

Randgold looks to get more out of Tongon mine



2:12a

Ryanair profit soars 55%; warns on overcapacity



2:09a

Siemens and Bombardier in talks to form train JVs



2:09a

VW asks EU to scrutinize German car makers



2:03a

KKR close to announcing deal for WebMD



1:44a

Julius Baer assets under management jump



1:44a

Royal Philips profit rises, begins share buybacks



1:43a

Ryanair profit rises 55%, beating expectations












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


ARNI


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors

 



ARNI
U.S.: OTC


Join TD Ameritrade

Find a Broker


Arno Therapeutics Inc.

Watchlist 
CreateARNIAlert



  


Closed

Last Updated: Jul 21, 2017 5:20 p.m. EDT
Delayed quote



$
0.052



0.0116
28.71%






Previous Close




$0.0404





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




9.865% vs Avg.




                Volume:               
                
                    3.3K
                


                65 Day Avg. - 33.5K
            





Open: 0.0494
Close: 0.052



0.0300
Day Low/High
0.0520





Day Range



0.0101
52 Week Low/High
0.8855


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$0.0494



Day Range
0.0300 - 0.0520



52 Week Range
0.0101 - 0.8855



Market Cap
$2.57M



Shares Outstanding
49.35M



Public Float
20.14M



Beta
n/a



Rev. per Employee
n/a



P/E Ratio
n/a



EPS
$-0.44



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
n/a
n/a


% of Float Shorted
n/a



Average Volume
33.45K




 


Performance




5 Day


15.04%







1 Month


-3.70%







3 Month


67.74%







YTD


-72.19%







1 Year


-90.00%









  

 
 


Recent News



MarketWatch
Other Dow Jones




No Headlines Available











Up and Down the Ladder: The Latest Comings and Goings at Covance, Bristol and…

Jul. 25, 2014 at 8:42 a.m. ET
on The Wall Street Journal









Hedge Funds Raise Large-Cap Holdings


Feb. 25, 2010 at 2:38 p.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






Tracking George Soros's Portfolio - Q4 2016 Update


Feb. 17, 2017 at 8:56 a.m. ET
on Seeking Alpha





10-Q: ARNO THERAPEUTICS, INC


Nov. 14, 2016 at 4:19 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





10-Q: ARNO THERAPEUTICS, INC


Aug. 22, 2016 at 5:13 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Arno Therapeutics to raise $2.8M via direct placement


Aug. 16, 2016 at 9:27 a.m. ET
on Seeking Alpha





Past Failures Set Arno Therapeutics Up For Success.


Jan. 28, 2016 at 8:59 a.m. ET
on Seeking Alpha





Insiders Roundup: Top Buys, Sales of the Week


Jan. 15, 2016 at 12:43 p.m. ET
on GuruFocus.com





Opko Health: Why Recent Weakness Represents A Golden Buying Opportunity


Jul. 24, 2015 at 8:10 a.m. ET
on Seeking Alpha





Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015


May. 4, 2015 at 8:31 a.m. ET
on Seeking Alpha





Biotech Weekly: Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015


May. 4, 2015 at 8:31 a.m. ET
on Seeking Alpha





Arno Therapeutics: A Likely Acquisition For Opko


Dec. 17, 2013 at 1:54 p.m. ET
on Seeking Alpha





Hedge Funds Raise Large-Cap Holdings


Feb. 25, 2010 at 2:38 p.m. ET
on The Wall Street Journal







No Headlines Available








Arno Therapeutics Inc.


            
            Arno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. It develops pre-clinical and clinical-stage product under the following brands: Onapristone, AR-42, and AR-12. The company was founded by Peter Morgan Kash, David M. Tanen, and Joshua A. Kazam in March 2000 and is headquartered in Flemington, NJ.

            
            (See Full Profile)


  



 


Competitors




Name
Chg %
Market Cap




Nektar Therapeutics
0.32%
$3.45B


Sucampo Pharmaceuticals Inc. Cl A
0.46%
$508.79M


MediciNova Inc.
2.26%
$187.18M


Chimerix Inc.
-1.57%
$233.25M


Catalyst Biosciences Inc.
1.42%
$18.23M




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





GOOGL

0.17%








CRBP

0.00%








BZUN

8.33%








ITW

0.12%








NYT

0.28%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.













Stocks Index - Markets Index
























Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




2:45 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



















































Stocks Index - Markets Index
























Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Browse Stocks
Stocks A-Z


0-9ABCDEFGHIJKLMNOPQRSTUVWXYZOther

Browse by Location

Argentina
Australia
Austria
Bahamas
Bahrain
Belgium
Bermuda
Botswana
Brazil
British Virgin Islands
Canada
Cayman Islands
Chile
China
Colombia
Curacao
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Gibraltar
Greece
Hong Kong
Hungary
Iceland
India
Indonesia
Ireland
Isle of Man
Israel
Italy
Japan
Jordan
Kazakhstan
Kuwait
Latvia
Lebanon
Liechtenstein
Lithuania
Luxembourg
Malaysia
Malta
Mauritius
Mexico
Monaco
Money Rates
Morocco
Namibia
Netherlands
New Zealand
Norway
Oman
Pakistan
Panama
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Thailand
Tunisia
Turkey
Ukraine
United Arab Emirates
United States
Venezuela
Western Samoa












Log In




2:45 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



















































Stocks/Country/United States Index - Markets Index
























Bulletin






Investor Alert







London Markets Open in:



Asia Markets
Currencies
US Market Snapshot
















Stocks
Rates
Funds
Bonds
Benchmarks
Real Estate Investment Trusts
Futures
American Depository Receipt Stocks
Exchange Traded Notes
Warrants
Indexes
Exchange Traded Funds
Currencies
Crypto Currencies

Location: United States



Name
Exchange
Sector




01 Communique Laboratory Inc. (OCQLF)
OOTC
Software


1347 Property Insurance Holdings Inc. (PIH)
XNAS
Non-Life Insurance


1-800-FLOWERS.COM Inc. Cl A (FLWS)
XNAS
Specialty Retail


1pm Industries Inc. (OPMZ)
OOTC
Food Products


1st Capital Bank (CA) (FISB)
OOTC
Banking


1st Constitution Bancorp (FCCY)
XNAS
Banking


1st NRG Corp. (FNRC)
OOTC
Oil Extraction


1st Source Corp. (SRCE)
XNAS
Banking


2050 Motors Inc. (ETFM)
OOTC
Automobiles


21st Century Fox Inc. Cl A (FOXA)
XNAS
Broadcasting


21st Century Fox Inc. Cl B (FOX)
XNAS
Broadcasting


21Vianet Group Inc. ADR (VNET)
XNAS
Internet/Online


22nd Century Group Inc. (XXII)
XASE
Biotechnology


24/7 Kid Doc Inc. (TVMD)
OOTC
Healthcare Provision


2U Inc. (TWOU)
XNAS
Software


2xLeveraged Long E-TRACS Linked to Wells Fargo Business Development Co. Index 052441 (BDCL)
ARCX
Major International Banks


2xLeveraged Long ETRACS Wells Fargo Business Development (LBDC)
ARCX
Major International Banks


3D Eye Solutions Inc. (TDEY)
OOTC
Motion Picture/Sound Recording


3D Pioneer Systems Inc. (DPSM)
OOTC
Software


3D Systems Corp. (DDD)
XNYS
Computers/Consumer Electronics


3DIcon Corp. (TDCP)
OOTC
Software


3Dshopping.com (THDS)
OOTC
Mixed Retailing


3DX Industries Inc. (DDDX)
OOTC
Computers/Consumer Electronics


3i Group PLC ADR (TGOPY)
OOTC
Finance Companies


3M Co. (MMM)
XNYS
Diversified Holding Companies


3Pea International Inc. (TPNL)
XOTC
Accounting


3Power Energy Group Inc. (PSPW)
OOTC
Renewable Energy Generation


3TL Technologies Corp. (TTMZF)
OOTC
Advertising/Marketing/Public Relations


420 Property Management Inc. (FTPM)
OOTC
Real Estate Agents/Brokers


4Cable TV International Inc. (CATV)
OOTC
Diversified Business Services


4Licensing Corp. (FOURQ)
OOTC
Diversified Business Services


500.com Ltd. ADR (WBAI)
XNYS
Gambling Industries


51job Inc. ADR (JOBS)
XNAS
Employment/Training Services


58.com Inc. ADR (WUBA)
XNYS
Consumer Services


5Barz International Inc. (BARZ)
OOTC
Networking


5N Plus Inc. (FPLSF)
OOTC
Commodity Chemicals


6D Global Technologies Inc. (SIXD)
OOTC
Computer Services


808 Renewable Energy Corp. (RNWR)
OOTC
Multiutilities


88 Energy Ltd. ADR (TNGRY)
OOTC
Oil Extraction


888 Holdings PLC (EIHDF)
OOTC
Gambling Industries


8Point3 Energy Partners LP (CAFD)
XNAS
Renewable Energy Generation


8X8 Inc. (EGHT)
XNAS
Wired Telecommunications Services


A Clean Slate Inc. (DRWN)
OOTC
Diversified Business Services


A&W Revenue Royalties Income Fund (AWRRF)
OOTC
Restaurants


A. H. Belo Corp. Series A (AHC)
XNYS
Publishing


A. Schulman Inc. (SHLM)
XNAS
Commodity Chemicals


A. Schulman Inc. 6% Pfd. (SLMNP)
OOTC
Commodity Chemicals


A.D. Makepeace Co. (MAKE)
OOTC
Farming


A.M. Castle & Co. (CAS)
XNYS
Wholesalers


A.O. Smith Corp. (AOS)
XNYS
Building Materials/Products


A.P. Moeller-Maersk A/S ADR (AMKBY)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series A (AMKAF)
OOTC
Water Transport/Shipping


A.P. Moeller-Maersk A/S Series B (AMKBF)
OOTC
Water Transport/Shipping


A.S. Roma S.p.A. (ASRAF)
OOTC
Recreational Services


A-1 Group Inc. (AWON)
OOTC
Tobacco


A10 Networks Inc. (ATEN)
XNYS
Computer Services


a2 Milk Co. Ltd. (ACOPF)
OOTC
Biotechnology


AAC Holdings Inc. (AAC)
XNYS
Healthcare Provision


AAC Technologies Holdings Inc. (AACAF)
OOTC
Industrial Electronics


AAC Technologies Holdings Inc. ADR (AACAY)
OOTC
Industrial Electronics


AAON Inc. (AAON)
XNAS
Building Materials/Products


AAP Inc. (AAPJ)
OOTC
Food Products


AAR Corp. (AIR)
XNYS
Aerospace Products/Parts


Aaron's Inc. (AAN)
XNYS
Consumer Services


AB Science S.A. (ABSCF)
OOTC
Pharmaceuticals


AB Svensk Exportkredit ELEMENTS linked to MLCX Biofuels Index Total Return (FUE)
ARCX
Finance Companies


AB Svensk Exportkredit ELEMENTS linked to MLCX Grain Index Total Return (GRU)
ARCX
Finance Companies


AB&T Financial Corp. (ABTO)
OOTC
Banking


Abacus Mining & Exploration Corp. (ABCFF)
OOTC
General Mining


Abakan Inc. (ABKI)
OOTC
Industrial Products


Abattis Bioceuticals Corp. (ATTBF)
OOTC
Biotechnology


Abaxis Inc. (ABAX)
XNAS
Medical Equipment/Supplies


ABB Ltd. (ABLZF)
OOTC
Industrial Machinery


ABB Ltd. ADR (ABB)
XNYS
Industrial Machinery


Abbott Laboratories (ABT)
XNYS
Pharmaceuticals


AbbVie Inc. (ABBV)
XNYS
Biotechnology


Abby Inc. (ABBY)
OOTC
Oil Extraction


Abcam PLC (ABCZF)
OOTC
Biotechnology


Abcam PLC ADR (ABCZY)
OOTC
Biotechnology


ABCO Energy Inc. (ABCE)
OOTC
Industrial Machinery


Abcourt Mines Inc. (ABMBF)
OOTC
General Mining


Aben Resources Ltd. (ABNAF)
OOTC
General Mining


Abengoa S.A. B (AGOAF)
OOTC
Construction


Abeona Therapeutics Inc. (ABEO)
XNAS
Biotechnology


Abeona Therapeutics Inc. Wt (ABEOW)
XNAS



Abercrombie & Fitch Co. (ANF)
XNYS
Clothing Retail


Aberdeen Asia-Pacific Income Fund Inc. (FAX)
XASE
Closed-End Funds


Aberdeen Asia-Pacific Income Investment Co. Ltd. (ABAKF)
OOTC
Closed-End Funds


Aberdeen Asset Management PLC (ABDNF)
OOTC
Investment Advisors


Aberdeen Asset Management PLC ADR (ABDNY)
OOTC
Investment Advisors


Aberdeen Australia Equity Fund Inc. (IAF)
XASE
Closed-End Funds


Aberdeen Chile Fund Inc. (CH)
XASE
Closed-End Funds


Aberdeen Emerging Markets Smaller Company Opportunities Fund Inc. (ABE)
XASE
Closed-End Funds


Aberdeen Global Income Fund Inc. (FCO)
XASE
Closed-End Funds


Aberdeen Greater China Fund Inc. (GCH)
XNYS
Closed-End Funds


Aberdeen Indonesia Fund Inc. (IF)
XASE
Closed-End Funds


Aberdeen International Inc. (AABVF)
OOTC
General Mining


Aberdeen Israel Fund Inc. (ISL)
XASE
Closed-End Funds


Aberdeen Japan Equity Fund Inc. (JEQ)
XNYS
Closed-End Funds


Aberdeen Latin America Equity Fund Inc. (LAQ)
XASE
Closed-End Funds


Aberdeen Singapore Fund Inc. (SGF)
XNYS
Closed-End Funds


Abertis Infraestructuras S.A. ADR (ABRTY)
OOTC
Transportation Services


Ability Inc. (ABIL)
XNAS
Precision Products


Ability Inc. Wt (ABIWF)
OOTC



Abiomed Inc. (ABMD)
XNAS
Medical Equipment/Supplies


Abitibi Royalties Inc. (ATBYF)
OOTC
General Mining


Able Energy Inc. (ABLE)
OOTC
Gas Utilities


Ablynx N.V. (ABLYF)
OOTC
Biotechnology


ABM Industries Inc. (ABM)
XNYS
Diversified Business Services


Abraxas Petroleum Corp. (AXAS)
XNAS
Oil Extraction


Absecon Bancorp (ASCN)
OOTC
Banking


Absolute Health & Fitness Inc. (AHFI)
OOTC
Recreational Services


Absolute Software Corp. (ALSWF)
OOTC
Software


ABT Holdings Inc. (ABOT)
OOTC
Precious Metals


Abtech Holdings Inc. (ABHD)
OOTC
Industrial Machinery


ABV Consulting Inc. (ABVN)
OOTC
Advertising/Marketing/Public Relations


AC Immune S.A. (ACIU)
XNAS
Biotechnology


Acacia Communications Inc. (ACIA)
XNAS
Networking


Acacia Diversified Holdings Inc. (ACCA)
OOTC
Specialty Retail


Acacia Mining PLC (ABGLF)
OOTC
Gold


Acacia Research Corp. - Acacia Technologies (ACTG)
XNAS
Diversified Business Services


Acadia Healthcare Co. Inc. (ACHC)
XNAS
Healthcare Provision


ACADIA Pharmaceuticals Inc. (ACAD)
XNAS
Biotechnology


Acadia Realty Trust (AKR)
XNYS



Acadian Timber Corp. (ACAZF)
OOTC
Forestry & Wood Products


Acasti Pharma Inc. (ACST)
XNAS
Pharmaceuticals


Accelera Innovations Inc. (ACNV)
OOTC
Healthcare Provision


Accelerate Diagnostics Inc. (AXDX)
XNAS
Biotechnology


Accelerize Inc. (ACLZ)
XOTC
Life Insurance


Acceleron Pharma Inc. (XLRN)
XNAS
Biotechnology


Accenture PLC Cl A (ACN)
XNYS
Diversified Business Services


Access National Corp. (ANCX)
XNAS
Banking


Access Power Inc. (ACCR)
OOTC
Wired Telecommunications Services


Access Worldwide Communications Inc. (AWWC)
OOTC
Advertising/Marketing/Public Relations


Acciona S.A. (ACXIF)
OOTC
Construction


ACCO Brands Corp. (ACCO)
XNYS
Nondurable Household Products


Accor S.A. (ACRFF)
OOTC
Hotels


Accor S.A. ADR (ACCYY)
OOTC
Hotels


Accordia Golf Co. Ltd. (ACGFF)
OOTC
Recreational Services


Accredited Mortgage Loan REIT Trust 9.75% Perp. Cum. Pfd. Series A (AHHAP)
OOTC
Mortgages


Accretive Health Inc. (ACHI)
OOTC
Healthcare Provision


Accuray Inc. (ARAY)
XNAS
Medical Equipment/Supplies


Accuride Corp. (ACW)
XNYS
Auto & Commercial Vehicle Parts


AcelRx Pharmaceuticals Inc. (ACRX)
XNAS
Pharmaceuticals


Acer Inc. GDR Reg S (ACEYY)
OOTC
Computers/Consumer Electronics


Acerus Pharmaceuticals Corp. (TRLPF)
OOTC
Biotechnology


Aceto Corp. (ACET)
XNAS
Specialty Chemicals


Achaogen Inc. (AKAO)
XNAS
Biotechnology


Achillion Pharmaceuticals Inc. (ACHN)
XNAS
Biotechnology


ACI Worldwide Inc. (ACIW)
XNAS
Software



«1234567891011-2021-3031-4041-5051-6061-7071-8081-9091-94»










Log In




2:45 AM EDT
July 24, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
2:28aReckitt Benckiser profit rises on reduced costs
2:15aChinese regulator tells insurers to shape up
2:14aRandgold looks to get more out of Tongon mine
2:12aRyanair profit soars 55%; warns on overcapacity
2:10aSiemens and Bombardier in talks to form train JVs
2:09aVW asks EU to scrutinize German car makers
2:04aKKR close to announcing deal for WebMD
1:45aJulius Baer assets under management jump
1:44aRoyal Philips profit rises, begins share buybacks
1:44aRyanair profit rises 55%, beating expectations
1:34aHow OPEC committee’s coming meeting could make or break oil prices
1:32aOil prices steady with all eyes on OPEC meeting
1:13aJapan, Aussie stocks knocked by weak dollar, commodity prices
12:53aIMF cuts U.S. growth forecast for 2017, 2018
11:22p‘Game of Thrones’: The four biggest takeaways from 'Stormborn’
11:09pWhy you’re more likely to die in an accident during the summer months
11:09pThese wealthy parents spend $20,000 for summer camps so their kids can be ‘normal’
11:07p5 totally avoidable reasons why millennials can’t have nice things (or save any money)
11:06pHow Elon Musk and shorter commutes could transform people’s lives
11:05pJohn McCain is a war hero — but think twice before saying he’s ‘battling’ cancer 
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15


















































ARNI Stock Price - Arno Therapeutics Inc. Stock Quote (U.S.: OTC) - MarketWatch



























 














































 















Sections

Watchlist




























Signup
 • 
Login

Search







Bulletin











US
Europe
Asia
FX
Rates
Futures


Range


1D
5D
1M
3M
6M
1Y
2Y











Dow

21,580.07


-31.71


-0.15%











S&P 500

2,472.54


-0.91


-0.04%











Nasdaq

6,387.75


-2.25


-0.04%











GlobalDow

2,831.96


-1.24


-0.04%











Gold

1,258.90


-2.10


-0.17%











Oil

45.79


0.02


0.04%

















S&P 500 Movers(%)



CTAS 
9.2




COF 
8.6




ETFC 
5.1




SYF 
4.5






HP
-5.5




ISRG
-4.6




HBAN
-4.4




CHK
-3.1














Latest NewsAll Times Eastern








2:27a

Reckitt Benckiser profit rises on reduced costs



2:14a

Chinese regulator tells insurers to shape up



2:13a

Randgold looks to get more out of Tongon mine



2:12a

Ryanair profit soars 55%; warns on overcapacity



2:09a

Siemens and Bombardier in talks to form train JVs



2:09a

VW asks EU to scrutinize German car makers



2:03a

KKR close to announcing deal for WebMD



1:44a

Julius Baer assets under management jump



1:44a

Royal Philips profit rises, begins share buybacks



1:43a

Ryanair profit rises 55%, beating expectations












to be replaced

























































































































    




Home


Investing


Quotes


Stocks


United States


ARNI


Overview



Compare Quotes
Stock Screener
Earnings Calendar
Sectors

 



ARNI
U.S.: OTC


Join TD Ameritrade

Find a Broker


Arno Therapeutics Inc.

Watchlist 
CreateARNIAlert



  


Closed

Last Updated: Jul 21, 2017 5:20 p.m. EDT
Delayed quote



$
0.052



0.0116
28.71%






Previous Close




$0.0404





  









Advanced Charting


1D
5D
1M
3M
6M
YTD
1Y
3Y
All




$
%
Vol


Advanced Charting

  




9.865% vs Avg.




                Volume:               
                
                    3.3K
                


                65 Day Avg. - 33.5K
            





Open: 0.0494
Close: 0.052



0.0300
Day Low/High
0.0520





Day Range



0.0101
52 Week Low/High
0.8855


   








Your Watchlist



Customize MarketWatch
Have Watchlists? Log in to see them here or sign up to get started.

Create Account

                    … or Log In

















Symbol
Last
Chg
Chg %

















No Items in Watchlist
There are currently no items in this Watchlist.

Add Ticker to Watchlist




 (Go to Your Watchlist) 




No Saved Watchlists
Create a list of the investments you want to track.

Create Watchlist

                    …or try this starter list






Uh oh
Something went wrong while loading Watchlist.

Go to Watchlist



 

Recently Viewed Tickers



No Recent Tickers
Visit a quote page and your recently viewed tickers will be displayed here.

Search Tickers



















   





Overview


Profile


News


Charts


Financials


Historical Quotes


Analyst Estimates


Options


SEC Filings


Insiders



   




Key Data



Open
$0.0494



Day Range
0.0300 - 0.0520



52 Week Range
0.0101 - 0.8855



Market Cap
$2.57M



Shares Outstanding
49.35M



Public Float
20.14M



Beta
n/a



Rev. per Employee
n/a



P/E Ratio
n/a



EPS
$-0.44



Yield
n/a



Dividend
n/a



Ex-Dividend Date
n/a



Short Interest
n/a
n/a


% of Float Shorted
n/a



Average Volume
33.45K




 


Performance




5 Day


15.04%







1 Month


-3.70%







3 Month


67.74%







YTD


-72.19%







1 Year


-90.00%









  

 
 


Recent News



MarketWatch
Other Dow Jones




No Headlines Available











Up and Down the Ladder: The Latest Comings and Goings at Covance, Bristol and…

Jul. 25, 2014 at 8:42 a.m. ET
on The Wall Street Journal









Hedge Funds Raise Large-Cap Holdings


Feb. 25, 2010 at 2:38 p.m. ET
on The Wall Street Journal














Recent News



Other News
Press Releases






Tracking George Soros's Portfolio - Q4 2016 Update


Feb. 17, 2017 at 8:56 a.m. ET
on Seeking Alpha





10-Q: ARNO THERAPEUTICS, INC


Nov. 14, 2016 at 4:19 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





10-Q: ARNO THERAPEUTICS, INC


Aug. 22, 2016 at 5:13 p.m. ET
on Edgar Online -  (EDG = 10Q, 10K)





Arno Therapeutics to raise $2.8M via direct placement


Aug. 16, 2016 at 9:27 a.m. ET
on Seeking Alpha





Past Failures Set Arno Therapeutics Up For Success.


Jan. 28, 2016 at 8:59 a.m. ET
on Seeking Alpha





Insiders Roundup: Top Buys, Sales of the Week


Jan. 15, 2016 at 12:43 p.m. ET
on GuruFocus.com





Opko Health: Why Recent Weakness Represents A Golden Buying Opportunity


Jul. 24, 2015 at 8:10 a.m. ET
on Seeking Alpha





Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015


May. 4, 2015 at 8:31 a.m. ET
on Seeking Alpha





Biotech Weekly: Small Cap Biotechs Under $1 Billion Market Cap To Watch Into ASCO 2015


May. 4, 2015 at 8:31 a.m. ET
on Seeking Alpha





Arno Therapeutics: A Likely Acquisition For Opko


Dec. 17, 2013 at 1:54 p.m. ET
on Seeking Alpha





Hedge Funds Raise Large-Cap Holdings


Feb. 25, 2010 at 2:38 p.m. ET
on The Wall Street Journal







No Headlines Available








Arno Therapeutics Inc.


            
            Arno Therapeutics, Inc. operates as a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. It develops pre-clinical and clinical-stage product under the following brands: Onapristone, AR-42, and AR-12. The company was founded by Peter Morgan Kash, David M. Tanen, and Joshua A. Kazam in March 2000 and is headquartered in Flemington, NJ.

            
            (See Full Profile)


  



 


Competitors




Name
Chg %
Market Cap




Nektar Therapeutics
0.32%
$3.45B


Sucampo Pharmaceuticals Inc. Cl A
0.46%
$508.79M


MediciNova Inc.
2.26%
$187.18M


Chimerix Inc.
-1.57%
$233.25M


Catalyst Biosciences Inc.
1.42%
$18.23M




Competitor Data Provided By


   






   



























Partner Content























Trending Tickers
Powered by 





GOOGL

0.17%








CRBP

0.00%








BZUN

8.33%








ITW

0.12%








NYT

0.28%
























Advanced Search







Stocks



Columns


Authors


Topics







No results found





























Video Center










Learn more.Storyful, a division of News Corp, which owns MarketWatch, is a leading social media services company headquartered in Dublin, Ireland. Storyful combines world class journalism with industry-leading technology to discover, verify and acquire original content and provide the on-the-ground sources news and media organizations need to tell the stories that matter to their audience.











404 Not Found

Not Found
The requested URL /pr130510.html was not found on this server.
Additionally, a 404 Not Found
error was encountered while trying to use an ErrorDocument to handle the request.

